Labcorp EVP receives new stock option and RSU grants

Labcorp Holdings Inc. executive Kathryn W. Kyle, EVP and Chief Legal Officer, reported new equity awards.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Labcorp Holdings Inc. executive Kathryn W. Kyle, EVP and Chief Legal Officer, reported new equity awards. On February 10, 2026, she received 2,700 non-qualified stock options with an exercise price of $284.5 per share, granted under the Labcorp 2025 Omnibus Incentive Plan. These options vest in three equal annual installments starting on the grant date and are exercisable until February 9, 2036.

She was also granted 880 Restricted Stock Units (RSUs), each representing one share of common stock. The RSUs vest in three equal annual installments beginning on February 10, 2027. After this grant, she holds a total of 2,480 RSUs directly.

Insider Trade Summary

Grant/Award: 3,580 shares

Grant/Award 2 txns

Insider Kyle Kathryn W

Role EVP, Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Non-qualified Stock Options	2,700	$0.00	$0.00
Grant/Award	Restricted Stock Unit	880	$0.00	$0.00

Holdings After Transaction: Non-qualified Stock Options — 2,700 contracts (Direct); Restricted Stock Unit — 2,480 contracts (Direct)

Footnotes (5)

F1. Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan.
F2. The option vests in three equal annual installments beginning on the date reflected in this column.
F3. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
F4. The Restricted Stock Units vest in three equal annual installments beginning on February 10, 2027.
F5. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Labcorp (LH) report for Kathryn W. Kyle?

Labcorp reported equity awards to EVP and Chief Legal Officer Kathryn W. Kyle. She received 2,700 non-qualified stock options and 880 Restricted Stock Units on February 10, 2026, as part of the company’s incentive compensation programs.

How many Labcorp (LH) stock options were granted to Kathryn W. Kyle?

Kathryn W. Kyle was granted 2,700 non-qualified stock options. These options carry an exercise price of $284.5 per share and vest in three equal annual installments, starting on the February 10, 2026 grant date, and are exercisable through February 9, 2036.

What Restricted Stock Unit (RSU) grant did Labcorp (LH) disclose for Kathryn W. Kyle?

Labcorp disclosed that Kathryn W. Kyle received 880 Restricted Stock Units. Each RSU represents one share of Labcorp common stock and vests in three equal annual installments beginning on February 10, 2027, aligning with the company’s long-term incentive structure.

What is Kathryn W. Kyle’s RSU balance in Labcorp (LH) after the new grant?

After the February 10, 2026 RSU grant, Kathryn W. Kyle beneficially owns 2,480 Restricted Stock Units. This figure represents the aggregate number of RSUs held directly by her, reflecting previously granted units plus the newly awarded 880 units.

Under which plan were Kathryn W. Kyle’s Labcorp (LH) stock options granted?

The employee stock options granted to Kathryn W. Kyle were issued under the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan. This plan governs equity-based compensation awards such as non-qualified stock options to executives and other eligible participants.

How do the vesting schedules work for Kathryn W. Kyle’s Labcorp (LH) equity awards?

Her 2,700 stock options vest in three equal annual installments beginning on the February 10, 2026 grant date. The 880 Restricted Stock Units vest separately, also in three equal annual installments, but starting later on February 10, 2027, extending long-term retention.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/12/2026 - 03:43 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kyle Kathryn W

(Last)

(First)

(Middle)

531 SOUTH SPRING STREET

(Street)

BURLINGTON

27215

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
LABCORP HOLDINGS INC. [ LH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-qualified Stock Options⁽¹⁾	$284.5	02/10/2026		A		2,700		02/10/2027⁽²⁾	02/09/2036	Common Stock	2,700	$0	2,700	D
Restricted Stock Unit	⁽³⁾	02/10/2026		A		880		⁽⁴⁾	⁽⁴⁾	Common Stock	880	$0	2,480⁽⁵⁾	D

Explanation of Responses:

1. Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan.

2. The option vests in three equal annual installments beginning on the date reflected in this column.

3. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

4. The Restricted Stock Units vest in three equal annual installments beginning on February 10, 2027.

5. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

	/s/ Kathryn W. Kyle	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR